Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
- 5 December 2006
- journal article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 25 (3), 265-270
- https://doi.org/10.1007/s10637-006-9020-9
Abstract
Purpose: The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma. Methods: Patients with advanced urothelial carcinoma that had relapsed after receiving perioperative chemotherapy, or progressed on first-line chemotherapy for metastatic disease, were eligible for enrollment. Patients received pemetrexed 500 mg/m2 every 21 days along with folic acid and vitamin B12 supplementation. Results: A total of 13 patients were enrolled. An objective response was achieved in 1/12 evaluable patients for an overall response rate of 8% (90% upper limit 29%). This level of activity did not meet criteria for expansion based on the pre-defined optimal 2-stage Simon design and the trial was concluded. Treatment was generally well tolerated, however, 2/13 patients developed febrile neutropenia. Non-hematologic grade ≥ 3 toxicity was rare. Conclusions: Pemetrexed as second-line therapy in advanced urothelial carcinoma is associated with modest activity. The role of this novel antifolate in chemotherapy-naïve patients warrants further investigation.Keywords
This publication has 20 references indexed in Scilit:
- Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the UrotheliumJournal of Clinical Oncology, 2006
- Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladderCancer, 2006
- A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimenBritish Journal of Cancer, 2006
- Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal FunctionJournal of Clinical Oncology, 2006
- Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinomaCancer, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Pemetrexed in bladder, head and neck, and cervical cancersSeminars in Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinumEuropean Journal of Cancer, 1998
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989